Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.70 |
| ▸ | DNTT | P04053 | 1/20 | 0.63 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3220655 | 0.89 | BACE1 (0.81) | BACE1DNTTPTGDR2MEN1KMT2A | |
| SCHEMBL3220639 | 0.89 | BACE1 (0.81) | BACE1DNTTPTGDR2MEN1KMT2A | |
| SCHEMBL5038610 | 0.87 | BACE1 (0.67) | BACE1DNTTMEN1KMT2AALDH1A1 | |
| SCHEMBL5038607 | 0.87 | BACE1 (0.67) | BACE1DNTTMEN1KMT2AALDH1A1 | |
| SCHEMBL9054395 | 0.84 | BACE1 (0.64) | BACE1DNTTPTGDR2MEN1KMT2A | |
| SCHEMBL8807280 | 0.83 | PTGDR2 (0.67) | BACE1DNTTPTGDR2MEN1KMT2A | |
| SCHEMBL9054524 | 0.83 | PTGDR2 (0.67) | BACE1DNTTPTGDR2MEN1KMT2A | |
| SCHEMBL3221709 | 0.83 | BACE1 (1.00) | BACE1DNTTMEN1KMT2AALDH1A1 | |
| SCHEMBL3221697 | 0.83 | BACE1 (1.00) | BACE1DNTTMEN1KMT2AALDH1A1 | |
| SCHEMBL10624957 | 0.81 | SNCA (0.62) | BACE1DNTTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9956202-B2 | Use of indolyl and indolinyl hydroxamates for treating neurodegenerative disorders or cognitive decicits | TAIPEI MEDICAL UNIVERSITY (TW) | 2018-05-01 | — | — | US | disclosed |
| US-9598364-B2 | Indolyl or indolinyl hydroxamate compounds | TAIPEI MEDICAL UNIVERSITY (TW) | 2017-03-21 | — | — | US | disclosed |
| US-20160303079-A1 | USE OF INDOLYL AND IDOLINYL HYDROXAMATES FOR TREATING NEURODEGENERATIVE DISORDERS OR COGNITIVE DECICITS | TAIPEI MEDICAL UNIVERSITY (TW) | 2016-10-20 | — | — | US | disclosed |
| US-9296692-B2 | Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury | TAIPEI MEDICAL UNIVERSITY (TW) | 2016-03-29 | — | — | US | disclosed |
| US-20150065552-A1 | Use of Indolyl and Indolinyl Hydroxamates for Treating Heart Failure of Neuronal Injury | TAIPEI MEDICAL UNIVERSITY (TW) | 2015-03-05 | — | — | US | disclosed |
| US-20140364477-A1 | INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS | TAIPEI MEDICAL UNIVERSITY (TW) | 2014-12-11 | — | — | US | disclosed |
| US-8846748-B2 | Indolyl or indolinyl hydroxamate compounds | TAIPEI MEDICAL UNIVERSITY (TW) | 2014-09-30 | — | — | US | disclosed |
| US-20110245315-A1 | INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS | TAIPEI MEDICAL UNIVERSITY (TW) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303079-A1 | USE OF INDOLYL AND IDOLINYL HYDROXAMATES FOR TREATING NEURODEGENERATIVE DISORDERS OR COGNITIVE DECICITS | IDO1, IDO2, HTT | BACE1 144/4885DNTT 1136/4885PTGDR2 2158/4885 |
| US-20150065552-A1 | Use of Indolyl and Indolinyl Hydroxamates for Treating Heart Failure of Neuronal Injury | TNNI3, NLN, TNNT2 | BACE1 1034/4885DNTT 2816/4885PTGDR2 2060/4885 |
| US-20110245315-A1 | INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS | IDH3A, IDH2, IDH3B | BACE1 3896/4885DNTT 1846/4885PTGDR2 1020/4885 |
| US-20140364477-A1 | INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS | IDH3A, IDH2, IDH3B | BACE1 3896/4885DNTT 1846/4885PTGDR2 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.